

Resource Summary Report

Generated by ASWG on Aug 9, 2026

BUV395 Rat Anti-Mouse CD4

RRID:AB_2734761

Type: Antibody

Proper Citation

BD Biosciences Cat# 740208, RRID:AB_2734761

Antibody Information

URL: http://antibodyregistry.org/AB_2734761

Proper Citation: BD Biosciences Cat# 740208, RRID:AB_2734761

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: BUV395 Rat Anti-Mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: RM4-5

Antibody ID: AB_2734761

Vendor: BD Biosciences

Catalog Number: 740208

Record Creation Time: 20250820T053208+0000

Record Last Update: 20250820T214737+0000

Ratings and Alerts

No rating or validation information has been found for BUV395 Rat Anti-Mouse CD4 .

No alerts have been found for BUV395 Rat Anti-Mouse CD4 .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wang L, et al. (2026) The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. *Developmental cell*, 61(6), 1208.

Dev S, et al. (2026) ATP7B-maintained copper stores in myeloid progenitors are required for functional maturation of neutrophils. *Cell reports*, 45(2), 116955.

Larsen RK, et al. (2025) Non-cell-autonomous tumor promotion in DICER1 cancer predisposition. *Developmental cell*.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. *Immunity*, 58(2), 499.

Allman A, et al. (2025) Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs. *Immunity*, 58(1), 143.

Reader CS, et al. (2025) The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes. *Anti-cancer drugs*, 36(6), 447.

Delaunay T, et al. (2024) Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity. *Cell reports. Medicine*, 5(5), 101528.

Wilson AL, et al. (2024) Leader cells promote immunosuppression to drive ovarian cancer progression in vivo. *Cell reports*, 43(11), 114979.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. *Cancer cell*, 42(10), 1676.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Salvador AFM, et al. (2023) Age-dependent immune and lymphatic responses after spinal cord injury. *Neuron*, 111(14), 2155.

Nyberg WA, et al. (2023) An evolved AAV variant enables efficient genetic engineering of murine T cells. *Cell*, 186(2), 446.

Dähling S, et al. (2022) Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. *Immunity*, 55(4), 656.

Liu H, et al. (2022) Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates Fc γ R-independent GITR agonism and antitumor activity. *Cell reports. Medicine*, 3(6), 100660.

Rustenhoven J, et al. (2021) Functional characterization of the dural sinuses as a neuroimmune interface. *Cell*, 184(4), 1000.

Okuniewska M, et al. (2021) SPNS2 enables T cell egress from lymph nodes during an immune response. *Cell reports*, 36(2), 109368.

Alterauge D, et al. (2020) Continued Bcl6 Expression Prevents the Transdifferentiation of Established Tfh Cells into Th1 Cells during Acute Viral Infection. *Cell reports*, 33(1), 108232.

Kim CJ, et al. (2018) The Transcription Factor Ets1 Suppresses T Follicular Helper Type 2 Cell Differentiation to Halt the Onset of Systemic Lupus Erythematosus. *Immunity*, 49(6), 1034.